Market Closed -
Nasdaq
21:30:00 24/05/2024 BST
|
5-day change
|
1st Jan Change
|
0.3125
USD
|
-3.55%
|
|
-3.70%
|
-90.23%
|
Fiscal Period: December |
2022
|
2023
|
2024
|
2025
|
---|
Capitalization
1 |
4.536
|
1.759
|
2.564
|
-
|
Enterprise Value (EV)
1 |
4.536
|
1.759
|
2.564
|
2.564
|
P/E ratio
|
-0.44
x
|
-
|
-0.44
x
|
-1.2
x
|
Yield
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
75.1
x
|
23.3
x
|
41.3
x
|
12.8
x
|
EV / Revenue
|
75.1
x
|
23.3
x
|
41.3
x
|
12.8
x
|
EV / EBITDA
|
-
|
-
|
-
|
-
|
EV / FCF
|
-
|
-
|
-
|
-
|
FCF Yield
|
-
|
-
|
-
|
-
|
Price to Book
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
489
|
550
|
8,204
|
-
|
Reference price
2 |
9.280
|
3.200
|
0.3125
|
0.3125
|
Announcement Date
|
27/02/23
|
21/02/24
|
-
|
-
|
Fiscal Period: December |
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Net sales
1 |
-
|
0.0604
|
0.0754
|
0.062
|
0.2
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-
|
-6.099
|
-4.876
|
-4.928
|
-5.119
|
Operating Margin
|
-
|
-10,090.21%
|
-6,466.82%
|
-7,948.39%
|
-2,559.5%
|
Earnings before Tax (EBT)
1 |
-
|
-7.606
|
-4.911
|
-4.928
|
-5.119
|
Net income
1 |
-4.95
|
-7.606
|
-4.911
|
-6.652
|
-6.205
|
Net margin
|
-
|
-12,583.62%
|
-6,513.75%
|
-10,729.03%
|
-3,102.5%
|
EPS
2 |
-14.08
|
-20.96
|
-
|
-0.7100
|
-0.2600
|
Free Cash Flow
|
-
|
-
|
-
|
-
|
-
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
04/03/22
|
27/02/23
|
21/02/24
|
-
|
-
|
Fiscal Period: December |
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
---|
Net sales
1 |
0.0107
|
0.0182
|
0.0225
|
0.0255
|
0.0171
|
-
|
0.0101
|
0.015
|
0.017
|
0.02
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-2.365
|
-1.633
|
-1.327
|
-1.181
|
-1.406
|
-
|
-1.275
|
-1.226
|
-1.214
|
-1.212
|
Operating Margin
|
-22,147.94%
|
-8,964.11%
|
-5,891.47%
|
-4,637.85%
|
-8,237.84%
|
-
|
-12,614.34%
|
-8,173.33%
|
-7,141.18%
|
-6,060%
|
Earnings before Tax (EBT)
1 |
-3.708
|
-1.633
|
-1.329
|
-1.183
|
-1.465
|
-
|
-2.399
|
-1.226
|
-1.214
|
-1.212
|
Net income
1 |
-3.836
|
-1.633
|
-1.329
|
-1.183
|
-1.465
|
-0.998
|
-2.399
|
-1.526
|
-1.514
|
-1.212
|
Net margin
|
-35,914.98%
|
-8,962.84%
|
-5,901.02%
|
-4,646.49%
|
-8,579.73%
|
-
|
-23,729.97%
|
-10,173.33%
|
-8,905.88%
|
-6,060%
|
EPS
2 |
-7.840
|
-3.360
|
-1.600
|
-2.400
|
-2.880
|
-1.920
|
-0.4400
|
-0.1500
|
-0.0700
|
-0.0600
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
15/08/22
|
14/11/22
|
27/02/23
|
03/07/23
|
25/08/23
|
14/11/23
|
15/05/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-
|
-
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
Capex
|
-
|
-
|
-
|
-
|
-
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
04/03/22
|
27/02/23
|
21/02/24
|
-
|
-
|
Last Close Price
0.3125
USD Average target price
1.5
USD Spread / Average Target +380.00% Consensus |
1st Jan change
|
Capi.
|
---|
| -90.23% | 2.66M | | +67.53% | 62.86B | | -0.77% | 41.38B | | +45.66% | 40.38B | | -10.72% | 27.64B | | +13.30% | 26.46B | | -22.79% | 18.9B | | +4.70% | 12.67B | | +24.10% | 12.27B | | +27.41% | 12.07B |
Other Biotechnology & Medical Research
|